November 22, 2012in IP Intensive, Patent Practice, Patents, Pharmaceutical Drugs1by Editor921 Subsequent Entry Biologic Litigation Set to Take Off in Canada The Canadian pharmaceutical industry is entering a new era as Subsequent Entry Biologic (SEB) litigation begins to emerge in the Canadian pharmaceutical landscape. Biologic drugs are derived through the metabolic…
